The diligence of a specialist team, in hours.
MedFuel Intel is an AI due-diligence platform built for healthcare investing. It produces a 12-section, institutional-grade report on a company — scientific, regulatory, reimbursement, IP, competitive, financial, and an investment-committee-ready memo — with every claim traced to the primary source behind it.
A month of analyst work, without the month.
Real healthcare diligence means reading clinical data, mapping an FDA pathway, checking who actually pays, pulling the patent estate, and pressure-testing the numbers — work that takes a specialist associate team weeks. MedFuel Intel runs that workflow across a five-phase research engine and specialist frameworks, then assembles it into one coherent report.
The difference from a generic AI summary is rigor: every claim is graded against its source, drawn from primary records — FDA databases, ClinicalTrials.gov, CMS coverage, SEC filings — not scraped blog posts. You get an answer you can actually underwrite a decision on.
Twelve specialist sections, one verdict.
Company & Management
Founders, leadership, and key hires assessed against the roles a venture at this stage actually needs.
Scientific & Clinical Evidence
Trial design, endpoints, and biomarker data read the way a scientific reviewer would read them.
Regulatory Pathway
FDA route, submission timeline, clearances and approvals — mapped to where the real risk sits.
Payer & Reimbursement
Coverage, coding, and the path to getting paid — often the true gating risk, not the science.
IP & Freedom to Operate
Patent estate, claim strength, and the competitive whitespace around it.
Competitive Landscape
Honest head-to-head positioning against the companies actually in the race.
Commercial Execution
Go-to-market, traction, and the evidence behind the revenue story.
Financial Model & Valuation
The numbers stress-tested, with every assumption made explicit.
Capital Structure
Cap table, prior rounds, and what this round actually buys.
Risk Matrix
The handful of risks that truly decide the outcome — ranked, not listed.
Investment Thesis & IC Memo
A committee-ready synthesis: the case, the risks, and a defensible verdict.
Exit Strategy
Likely acquirers and comparable transactions that frame the return.
Primary sources, not the open web.
MedFuel Intel reads the documents that actually matter — regulatory filings, trial registries, coverage determinations, and company disclosures — and cites them. When a fact can’t be confirmed, it says so.
- FDA 510(k) & PMA clearance databases
- ClinicalTrials.gov trial registry
- FDA MAUDE adverse-event reports
- CMS Medicare coverage & HCPCS coding
- SEC filings (Form D and beyond)
- Company disclosures & primary literature
Every claim carries its source.
The difference between professional diligence and theater is whether you can trace a statement back to where it came from. MedFuel Intel grades each claim so a reader always knows how much weight it can bear.
Confirmed against a primary source.
From a credible secondary source, not independently confirmed.
Modeled or derived, with assumptions stated.
Unsupported — and labeled so it can't masquerade as fact.
Intelligence that stays current.
Competitive Intel
Tracks rivals, clearances, and funding so a company's position is current — not a snapshot from the day you read it.
Deal Flow Scanner
Surfaces companies that match your thesis as they emerge across the sector.
Portfolio Risk
Watches your holdings for regulatory, clinical, and competitive shifts and flags what moved.
See a report for yourself.
Request access to MedFuel Intel, or ask us to walk you through a live report.